EPINEPHRINE AUTO-INJECTOR MARKET SIZE TO CROSS USD 2 BILLION BY 2025, GROWING AT A CAGR OF 8% DURING THE FORECAST PERIOD

Epinephrine Auto-Injector Market Size, Share, & Trends Analysis Report by Dosage (High, Low), Age Group (Below 6 Years, Between 6 & 12 years, Above 12 years), End-user (Hospitals & Clinics, Individuals, Others), Geography (APAC, North America, Europe, Latin America, and Middle East & Africa), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020–2025.

Prebook Tag
Licence Types What are these?
10 % OFF

on buying this report before the release date

GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

233 Pages

icon-table

52 Tables

icon-chart

136 Charts

icon-region

4 Regions

icon-country

15 Countries

icon-company

9 Companies

icon-market

5 Market Segment

EPHINEPHRINE AUTO-INJECTOR MARKET REPORT SCOPE

Report Attribute Details
MARKET SIZE (REVENUE) USD 2 BILLION (2025)
CAGR 8% (2020-2025)
Base Year 2019
Forecast Year 2020-2025
Market Segments Dosage (High, Low), Age Group (Below 6 Years, Between 6 & 12 years, Above 12 years), End-user (Hospitals & Clinics, Individuals, Others)
Geographic Analysis North America, Europe, APAC, Latin America, and Middle East & Africa
Countries Covered Argentina, Australia, Brazil, Canada, France, Germany, Israel, Japan, Netherlands, South Africa, South Korea, Spain, Turkey, UK, US

 MARKET DYNAMICS

The Epinephrine Auto-Injector Market Size to Cross USD 2 Billion By 2025, Growing at a CAGR Of 8%. The global epinephrine auto-injector market is expected to grow at a steady rate during the forecast period. The growth can be mainly attributed to the growing prevalence of anaphylaxis across demographics. Anaphylaxis is characterized as a potentially threatening systemic allergic reaction. It is most commonly triggered by medication, food allergies, or insect stings.

In US and the UK, the incidence of anaphylaxis is 40–500 per million persons, mortality is estimated at 0.63–0.76 per million. In the US, up to 5% population suffers from this condition. The clinical databases such as PubMed have captured the growing prevalence of anaphylaxis.

Globally, allergies caused by food items, food additives, latex, and dust are increasing at a steady rate. Such allergies, including anaphylaxis, are the most commonly prevalent in the US and the UK. Therefore, the growing incidence of anaphylaxis is likely to increase the high uptake of epinephrine as it the first-aid treatment option, thereby driving the global market.

SNIPPETS

  • The growing availability of generic epinephrine autoinjectors is one of the key drivers in the global market
  • North America is expected to witness an absolute growth of over 65% during the forecast period. The growth is due to the increase in the patient population and the wide availability of epinephrine auto-injectors
  • The high dose dosage segment is likely to observe an incremental growth of over $650 million. This growth is due to the high prevalence of anaphylaxis in teenage and adult patient groups
  • The above 12 years segment is expected to grow at a double-digit growth rate during the forecast period
  • The individuals’ end-user segment is projected to grow at a CAGR of over 9% during the period 2019–2025. The growth is on account of self-management of anaphylaxis through epinephrine auto-injectors

EPINEPHRINE AUTO-INJECTOR MARKET SEGMENTATION

This research report includes a detailed segmentation by 

  • dosage
  • age group
  • end-user
  • geography

INSIGHTS BY DOSAGE

The growing incidence of anaphylaxis in the adults & elderly is the primary factor driving the growth of the high dose segment. Epinephrine is considered as the first-line treatment for anaphylaxis. The increasing recommendation of high dose for adult patients is fueling the growth of the segment. Moreover, market players are also focusing on providing generic, low-cost products. This is increasing the demand for affordable treatment options for managing anaphylactic reactions.

The prevalence of food allergies is estimated to be high in children. Several studies have shown the majority of food allergy incidences, including anaphylaxis, occurs in schools or daycare centers. The National Institute of Allergy and Infectious Diseases guidelines recommend epinephrine as a first-line treatment option. Therefore, epinephrine auto-injectors are considered as an integral part of emergency care in schools and daycare centers.

The increasing prevalence of anaphylaxis in children is the key driver for the growth of the low dose segment. Further, the increasing commercialization of epinephrine auto-injectors for infants in the US and the approval of generic versions by the FDA are driving the growth of low dose segment market.

INSIGHTS BY AGE GROUP 

Several social and emotional factors contribute to the high prevalence of anaphylaxis in teenage and adult groups. Adults with peanut allergy have more severe reactions than children. HCPs recommend a safe dose (usually 0.3 mg) of epinephrine auto-injectors to the patient group aged 12 years and above.

Anaphylaxis in the elderly population tends to be threatening and requires intensified medical intervention. Therefore, managing the high risk of anaphylaxis in elderly people is expected to drive the uptake of epinephrine auto-injectors.

The burden of anaphylaxis among children is growing, hence it requires quick and effective management. Government and regulatory bodies are providing safeguards to prevent fatal reactions among children in the 6–12 years age group. Epinephrine through auto-injectors acts fast and can rapidly treat the most dangerous symptoms in children. Thus, it is always been recommended to make ready epinephrine auto-injectors for children in schools to avoid fatal conditions. Therefore, this is driving the segment growth.

In 2019, the below 6 years segment accounted for a 10% share of the global epinephrine auto-injector market. Children in this age group are prescribed to be treated with 0.15 mg/0.1 mg dose capacity.

An estimated 130% increase in emergency room visits for anaphylaxis among children reported between 2005 and 2014. The management of anaphylaxis in this age group is becoming a major concern among HCPs and parents. Vendors are focusing on introducing low-cost epinephrine auto-injectors for this age group.

INSIGHTS BY END-USER

The individual end-user segment accounted for the highest share and growth rate in 2019. This is mainly due to the growing demand for self-management of anaphylaxis. Individuals carry epinephrine auto-injectors for the treatment of sudden anaphylaxis shock. Hence, the segment is likely to emerge as a major revenue generator during the forecast period.

HCPs in hospitals & clinics are using epinephrine auto-injectors for the emergency management of anaphylaxis. The market is growing at a healthy rate. It is due to the high adoption of autoinjector devices by emergency departments in hospitals and clinics. The availability of skilled HCPs with knowledge and expertise also attracts many patients to hospitals and clinics.

Large and medium-sized hospitals are equipped with sophisticated healthcare infrastructure for emergency management of anaphylaxis. Hence, the share of this segment is likely to grow at a steady growth during the forecast period.

INSIGHTS BY GEOGRAPHY

North America dominates the epinephrine auto-injector market. The presence of a large disease population, coupled with better access to treatment for anaphylaxis, is the primary factor for its high market share. The strong presence of key players is also another reason for high product uptake in the region. Moreover, the rise in the anaphylactic patient pool and the launch of generic substitutes, which help to treat the condition effectively in adults and children groups, are likely to boost the growth during the forecast period.

Europe is the second-largest market. Better disease awareness, high healthcare spending, and the presence of key vendors are the primary factors for high shares. Germany, France, the UK, Spain, and the Netherlands are the major revenue contributors to the region. The Europe region is likely to be driven by the increasing treatment-seeking population due to increased awareness of anaphylactic reactions.

Japan, Australia, and South Korea are the major revenue contributors in APAC for epinephrine auto-injectors.

INSIGHTS BY VENDORS

The global epinephrine auto-injector market is highly consolidated. It is characterized by the presence of a few established vendors holding the majority of the shares. Vendors are offering several branded as well as generic epinephrine auto-injectors and are competing based on factors in terms of regulatory approvals, safety features, accurate dosing, convenience, technology, marketing strategies, and distribution channels.

Teva Pharmaceutical Industries offers generic version of Mylan’s EpiPen and EpiPen Jr to treat life- threatening anaphylaxis allergic reactions. Alk-Abello's epinephrine auto-injectors product line includes Jext 0.3 mg and 0.15 mg. The product gained wide popularity for the emergency treatment of anaphylactic shock.

The Epinephrine auto-injector research report includes in-depth coverage of the industry with growth rates, revenues & forecasts for the following segments:

Market Segmentation by Dosage  

  • High
  • Low

By Age Group 

  • Below 6 Years
  • Between 6 & 12 years
  • Above 12 years

By End-user  

  • Hospitals & Clinics
  • Individuals
  • Others

By Geography

  • Europe
    • Spain
    • Germany
    • Netherlands
    • France
    • UK
  • North America
    • US
    • Canada
  • APAC
    • South Korea
    • Japan
    • Australia
  • Latin America
    • Brazil
    • Argentina
  • MEA
    • Turkey
    • Israel
    • South Africa

Frequently Asked Questions

What is the Epinephrine auto-injector market size and growth rate?

The global epinephrine auto-injector market size to cross $2 billion by 2025, growing at a CAGR of over 8% during the forecast period.

What company are the leading manufacturers of Epipens and what is their market share?

Mylan, Teva Pharmaceutical Industries, Amneal Pharmaceuticals are the leading vendors in the market.

Which is the region will dominate the global epinephrine auto-injector market during the forecast period?

North America dominates the epinephrine auto-injector market. Europe is the second-largest market.

What is the market growth driver of the Epinephrine autoinjector market?

The following factors are likely to contribute to the growth of the epinephrine auto-injector market during the forecast period: Emergence of Innovative Solutions for Anaphylaxis Management Increasing Demand for Generic Epinephrine Auto-injectors at Pharma/Retail Stores Growing Demand for Self-administration of Drugs Availability of Generic Versions of Auto-injectors

Download Free Sample

The epinephrine auto-injector market is expected to grow at a CAGR of over 8% during the period 2019–2025.

 The following factors are likely to contribute to the growth of the epinephrine auto-injector market during the forecast period:

  • Emergence of Innovative Solutions for Anaphylaxis Management
  • Increasing Demand for Generic Epinephrine Auto-injectors at Pharma/Retail Stores
  • Growing Demand for Self-administration of Drugs
  • Availability of Generic Versions of Auto-injectors

Base Year:                  2019

Forecast Year:           2020–2025

The study considers the present scenario of the epinephrine auto-injector market and its market dynamics for the period 2019−2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The study offers both the demand and supply aspect of the market. It profiles and examines leading companies and other prominent companies operating in the market.

Key Vendors

  • Mylan
    • Business Overview
    • Major Product Offerings
    • Key Strengths
    • Key Strategies
    • Key Opportunities
  • Teva Pharmaceutical Industries
  • Amneal Pharmaceuticals

 Other Vendors

  • Adamis Pharmaceuticals
    • Business Overview
    • Major Product Offerings
    • Key Strengths
    • Key Strategies
    • Key Opportunities
  • ALK-Abelló
  • Bioprojet PHARMA
  • Bausch & Lomb
  • kaléo
  • Novartis

Market Segmentation by Dosage   

  • High
  • Low

Market Segmentation by Age Group 

  • Below 6 Years
  • Between 6 & 12 years
  • Above 12 years

Market Segmentation by End-user   

  • Hospitals & Clinics
  • Individuals
  • Others

Market Segmentation by Geography

  • Europe
    • Spain
    • Germany
    • Netherlands
    • France
    • UK
  • North America
    • US
    • Canada
  • APAC
    • South Korea
    • Japan
    • Australia
  • Latin America
    • Brazil
    • Argentina
  • MEA
    • Turkey
    • Israel
    • South Africa

1              Research Methodology

2              Research Objectives

3              Research Process

 

4              Scope & Coverage

4.1          Market Definition

4.1.1      Inclusion

4.1.2      Exclusion

4.2          Base Year

4.3          Scope of The Study

4.4          Market Segments

4.4.1      Market Segmentation by Dosage

4.4.2      Market Segmentation by Age Group

4.4.3      Market Segmentation by End-user

4.4.4      Market Segmentation by Geography

 

5              Report Assumptions & Caveats

5.1          Key Caveats

5.2          Currency Conversion

5.3          Market Derivation

 

6              Market at a Glance

7              Introduction

7.1          Anaphylaxis: Overview

7.1.1      Background

7.1.2      Epinephrine Auto-injectors for the Treatment of Anaphylaxis

7.2          Epinephrine Auto-injectors Market Snapshot

 

8              Market Opportunities & Trends

8.1          Emergence Of Innovative Solutions For Anaphylaxis Management

8.2          Vendors’ Growing Focus On Patient Assistance Programs

8.3          Increasing Demand For Generic Epinephrine Auto-Injectors At Pharma/Retail Stores

 

9              Market Growth Enablers

9.1          Rising Incidence Of Anaphylaxis

9.2          Growing Demand For Self-Administration Of Drugs

9.3          Availability Of Generic Versions Of Auto-Injectors

 

10           Market Restraints

10.1        Presence of Alternative Treatment Options

10.2        Adverse Side Effects Associated With Epinephrine Auto-Injectors

10.3        Shortage of Epinephrine Auto-Injectors

10.4        High Cost of Epinephrine Auto-Injectors

 

11           Market Landscape

11.1        Market Overview

11.2        Market Size & Forecast

11.3        Five Forces Analysis

11.3.1    Threat of New Entrants

11.3.2    Bargaining Power of Suppliers

11.3.3    Bargaining Power of Buyers

11.3.4    Threat of Substitutes

11.3.5    Competitive Rivalry

 

12           Dosage

12.1        Market Snapshot & Growth Engine

12.2        Market Overview

12.3        High Dose

12.3.1    Market Overview

12.3.2    Market Size & Forecast

12.4        Low Dose

12.4.1    Market Overview

12.4.2    Market Size & Forecast

 

13           Age Group

13.1        Market Snapshot & Growth Engine

13.2        Market Overview

13.3        Above 12 Years

13.3.1    Market Overview

13.3.2    Market Size & Forecast

13.4        6-12 Years

13.4.1    Market Overview

13.4.2    Market Size & Forecast

13.5        Below 6 Years

13.5.1    Market Overview

13.5.2    Market Size & Forecast

 

14           End-User

14.1        Market Snapshot & Growth Engine

14.2        Market Overview

14.3        Individuals

14.3.1    Market Overview

14.3.2    Market Size & Forecast

14.4        Hospitals & Clinics

14.4.1    Market Overview

14.4.2    Market Size & Forecast

14.5        Others

14.5.1    Market Overview

14.5.2    Market Size & Forecast

 

15           Geography

15.1        Market Snapshot & Growth Engine

15.2        Geographic Overview

 

16           North America

16.1        Market Overview

16.2        Market Size & Forecast

16.3        North America: Dosage Segmentation

16.3.1    Market Snapshot & Growth Engine

16.4        Key Countries

16.4.1    US: MARKET SIZE & FORECAST

16.4.2    Canada: MARKET SIZE & FORECAST

 

17           Europe

17.1        Market Overview

17.2        Market Size & Forecast

17.3        Europe: Dosage Segmentation

17.3.1    Market Snapshot & Growth Engine

17.4        Key Countries

17.4.1    Germany: Market Size & Forecast

17.4.2    France: Market Size & Forecast

17.4.3    UK: Market Size & Forecast

17.4.4    Spain: Market Size & Forecast

17.4.5    Netherlands: Market Size & Forecast

 

18           APAC

18.1        Market Overview

18.2        Market Size & Forecast

18.3        APAC: Dosage Segmentation

18.3.1    Market Snapshot & Growth Engine

18.4        Key Countries

18.4.1    Japan: Market Size & Forecast

18.4.2    Australia: Market Size & Forecast

18.4.3    South Korea: Market Size & Forecast

 

19           Middle-East & Africa

19.1        Market Overview

19.2        Market Size & Forecast

19.3        Middle-East & Africa: Dosage Segmentation

19.3.1    Market Snapshot & Growth Engine

19.4        Key Countries

19.4.1    Israel: Market Size & Forecast

19.4.2    South Africa: Market Size & Forecast

19.4.3    Turkey: Market Size & Forecast

 

20           Latin America

20.1        Market Overview

20.2        Market Size & Forecast

20.3        Latin America: Dosage Segmentation

20.3.1    Market Snapshot & Growth Engine

20.4        Key Countries

20.4.1    Brazil: Market Size & Forecast

20.4.2    Argentina: Market Size & Forecast

 

21           Competitive Landscape

21.1        Competition Overview

21.2        Market Share Analysis

21.2.1    Mylan

21.2.2    Teva Pharmaceutical Industries

21.2.3    Amneal Pharmaceuticals

21.2.4    Adamis Pharmaceuticals

21.2.5    ALK-Abelló

21.2.6    Bausch & Lomb

21.2.7    BIOPROJET PHARMA

21.2.8    kaléo

21.2.9    Novartis

 

22           Key Company Profiles

22.1        Mylan

22.1.1    Business Overview

22.1.2    Product Offerings

22.1.3    Key Strategies

22.1.4    Key Strengths

22.1.5    Key Opportunities

22.2        Teva Pharmaceutical Industries

22.2.1    Business Overview

22.2.2    Product Offerings

22.2.3    Key Strategies

22.2.4    Key Strengths

22.2.5    Key Opportunities

22.3        Amneal Pharmaceuticals

22.3.1    Business Overview

22.3.2    Product Offerings

22.3.3    Key Strategies

22.3.4    Key Strengths

22.3.5    Key Opportunities

 

23           Other Prominent Vendors

23.1        Adamis Pharmaceuticals

23.1.1    Business Overview

23.1.2    Product Offerings

23.1.3    Key Strategies

23.1.4    Key Strengths

23.1.5    Key Opportunities

23.2        ALK-Abelló

23.2.1    Business Overview

23.2.2    Product Offerings

23.2.3    Key Strategies

23.2.4    Key Strengths

23.2.5    Key Opportunities

23.3        BIOPROJET PHARMA

23.3.1    Business Overview

23.3.2    Product Offerings

23.3.3    Key Strategies

23.3.4    Key Strengths

23.3.5    Key Opportunities

23.4        Bausch & Lomb

23.4.1    Business Overview

23.4.2    Product Offerings

23.4.3    Key Strategies

23.4.4    Key Strengths

23.4.5    Key Opportunities

23.5        kaléo

23.5.1    Business Overview

23.5.2    Product Offerings

23.5.3    Key Strategies

23.5.4    Key Strengths

23.5.5    Key Opportunities

23.6        Novartis

23.6.1    Business Overview

23.6.2    Product Offerings

23.6.3    Key Strategies

23.6.4    Key Strengths

23.6.5    Key Opportunities

 

24           Report Summary

24.1        Key Takeaways

24.2        Strategic Recommendations

 

25           Quantitative Summary

25.1        Dosage

25.2        Age Group

25.3        End-User

25.4        Geography

25.5        North America: Dosage Segmentation

25.6        Europe: Dosage Segmentation

25.7        APAC: Dosage Segmentation

25.8        Middle East & Africa: Dosage Segmentation

25.9        Latin America: Dosage Segmentation

 

26           Appendix

26.1        Abbreviations

               

List of Exhibits 

Exhibit 1               Segmentation of Global Epinephrine Auto-injectors Market

Exhibit 2               Market Size Calculation Approach 2019

Exhibit 3               Major Symptoms of Anaphylaxis

Exhibit 4               Most Common Triggers of Anaphylaxis

Exhibit 5               Conditions where Epinephrine Auto-injectors are Used for Children Include

Exhibit 6               Major Market Dynamics of Global Epinephrine Auto-injectors Market

Exhibit 7               Global Epinephrine Auto-injectors Market by Geography 2019 (%)

Exhibit 8               Global Epinephrine Auto-injectors Market by Dosage 2019 (%)

Exhibit 9               Impact of Emergence of Innovative Solutions for Anaphylaxis Management

Exhibit 10             Impact of Vendors’ Growing Focus on Patient Assistance Programs

Exhibit 11             Mylan’s Patient Assistance Program Snapshot

Exhibit 12             Impact of Increasing Demand for Generic Epinephrine Auto-injectors at Pharma/Retail Stores

Exhibit 13             Impact of Rising Incidence of Anaphylaxis

Exhibit 14             Anaphylaxis Epidemiology 2000−2015

Exhibit 15             Hospital Admissions for All-cause Anaphylaxis (%)

Exhibit 16             Implications for Fatal Drug Anaphylaxis

Exhibit 17             Impact of Growing Demand for Self-administration of Drugs

Exhibit 18             Risk Factors to Consider Using Self-injectable Epinephrine

Exhibit 19             Impact of Availability of Generic Versions of Auto-injectors

Exhibit 20             Overview of Generic and Branded EpiPen Version

Exhibit 21             Impact of Presence of Alternative Treatment Options

Exhibit 22             Popular Alternative Methods for Anaphylaxis Treatment

Exhibit 23             Impact of Adverse Side Effects Associated with Epinephrine Auto-injectors

Exhibit 24             Common Side Effects of Epinephrine Auto-injectors

Exhibit 25             Some Rare Side-effects of Epinephrine

Exhibit 26             Adverse Effects of Epinephrine on Organs & Tissues

Exhibit 27             Impact of Shortage of Epinephrine Auto-injectors

Exhibit 28             Impact of High Cost of Epinephrine Auto-injectors

Exhibit 29             Average Price of Key Epinephrine Auto-injectors

Exhibit 30             Global Epinephrine Auto-injectors Market 2019–2025 ($ million)

Exhibit 31             Global Epinephrine Auto-injectors Market by Geography

Exhibit 32             Global Epinephrine Auto-injectors Market by Dosage

Exhibit 33             Global Epinephrine Auto-injectors Market by Age Group

Exhibit 34             Global Epinephrine Auto-injectors Market by End-user

Exhibit 35             Five Forces Analysis 2019

Exhibit 36             Incremental Growth by Dosage 2019 & 2025

Exhibit 37             Global Epinephrine Auto-injectors Market by Dosage

Exhibit 38             Global Epinephrine Auto-injectors Market by Dosage: Incremental Growth

Exhibit 39             Global Epinephrine Auto-injectors Market by Dosage: Absolute Growth

Exhibit 40             Global Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)

Exhibit 41             Global Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)

Exhibit 42             Global Epinephrine Auto-injectors Market by High Dose: Incremental and Absolute Growth

Exhibit 43             Usage of High Dose Epinephrine Auto-injectors

Exhibit 44             Global Epinephrine Auto-injectors Market by High Dose 2019–2025 ($ million)

Exhibit 45             Global Epinephrine Auto-injectors Market by Low Dose: Incremental & Absolute Growth

Exhibit 46             Usage of Low Dose Epinephrine Auto-injectors

Exhibit 47             Global Epinephrine Auto-injectors Market by Low Dose 2019–2025 ($ million)

Exhibit 48             Incremental Growth by Age Group 2019 & 2025

Exhibit 49             Global Epinephrine auto-injectors market by Age Group

Exhibit 50             Global Epinephrine Auto-injectors Market by Age Group: Incremental Growth

Exhibit 51             Global Epinephrine Auto-injectors Market by Age Group: Absolute Growth

Exhibit 52             Global Epinephrine Auto-injectors Market by Age Group 2019−2025 ($ million)

Exhibit 53             Global Epinephrine Auto-injectors Market by Age Group 2019−2025 (%)

Exhibit 54             Global Epinephrine Auto-injectors Market for Above 12 Years: Incremental & Absolute Growth

Exhibit 55             Yearly Prevalence of Emergent Patients with Anaphylaxis by Age Group 2010−2014

Exhibit 56             Global Epinephrine Auto-injectors Market for Above 12 Years 2019–2025 ($ million)

Exhibit 57             Global Epinephrine Auto-injectors Market for 6−12 Years: Incremental & Absolute Growth

Exhibit 58             Action of a Standard Epinephrine Auto-injector

Exhibit 59             Global Epinephrine Auto-injectors Market for 6−12 Years 2019–2025 ($ million)

Exhibit 60             Global Epinephrine Auto-injectors Market for Below 6 Years: Incremental & Absolute Growth

Exhibit 61             Global Epinephrine Auto-injectors Market for Below 6 Years 2019–2025 ($ million)

Exhibit 62             Incremental Growth by End-user 2019 & 2025

Exhibit 63             Global Epinephrine Auto-injectors Market by End-user

Exhibit 64             Global Epinephrine Auto-injectors Market by End-user: Incremental Growth

Exhibit 65             Global Epinephrine Auto-injectors Market by End-user: Absolute Growth

Exhibit 66             Global Epinephrine Auto-injectors Market by End-user 2019−2025 ($ million)

Exhibit 67             Global Epinephrine Auto-injectors Market by End-user 2019−2025 (%)

Exhibit 68             Global Epinephrine Auto-injectors Market by Individuals: Incremental & Absolute Growth

Exhibit 69             Global Epinephrine Auto-injectors Market by Individuals 2019–2025 ($ million)

Exhibit 70             Global Epinephrine Auto-injectors Market by Hospitals & Clinics: Incremental & Absolute Growth

Exhibit 71             Global Epinephrine Auto-injectors Market by Hospitals & Clinics 2019–2025 ($ million)

Exhibit 72             Epinephrine Auto-injectors Market by Others: Incremental & Absolute Growth

Exhibit 73             Global Epinephrine Auto-injectors Market by Others 2019–2025 ($ million)

Exhibit 74             Incremental Growth by Geography 2019 & 2025

Exhibit 75             Global Epinephrine Auto-injectors Market by Geography

Exhibit 76             Global Epinephrine Auto-Injectors Market by Geography 2019: Key Countries ($ million)

Exhibit 77             Global Epinephrine Auto-Injectors Market by Geography: Incremental Growth

Exhibit 78             Global Epinephrine Auto-Injectors Market by Geography: Absolute Growth

Exhibit 79             Global Epinephrine Auto-Injectors Market by Geography 2019−2025 ($ million)

Exhibit 80             Global Epinephrine Auto-Injectors Market by Geography 2019−2025 (%)

Exhibit 81             Epinephrine Auto-Injectors Market in North America in 2019

Exhibit 82             North America Epinephrine Auto-injectors Market: Incremental & Absolute Growth

Exhibit 83             Epinephrine Auto-injectors Market in North America 2019–2025 ($ million)

Exhibit 84             Incremental Growth by Dosage 2019 & 2025

Exhibit 85             North America Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)

Exhibit 86             North America Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)

Exhibit 87             Incremental Growth in North America 2019 & 2025

Exhibit 88             Epinephrine Auto-injectors Market in US 2019–2025 ($ million)

Exhibit 89             Epinephrine Auto-injectors Market in Canada 2019–2025 ($ million)

Exhibit 90             Epinephrine Auto-injectors Market in Europe 2019

Exhibit 91             Europe Epinephrine Auto-injectors Market: Incremental & Absolute Growth

Exhibit 92             Epinephrine Auto-injectors Market in Europe 2019–2025 ($ million)

Exhibit 93             Incremental Growth by Dosage 2019 & 2025

Exhibit 94             Europe Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)

Exhibit 95             Europe Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)

Exhibit 96             Incremental Growth in Europe 2019 & 2025

Exhibit 97             Knowledge Distribution about Emergency Kit for Managing Anaphylaxis among Teachers and Child-care Providers in Germany

Exhibit 98             Epinephrine Auto-injectors Market in Germany 2019–2025 ($ million)

Exhibit 99             Epinephrine Auto-injectors Market in France 2019–2025 ($ million)

Exhibit 100          Epinephrine Auto-injectors Market in UK 2019–2025 ($ million)

Exhibit 101          Epinephrine Auto-injectors Market in Spain 2019–2025 ($ million)

Exhibit 102          Epinephrine Auto-injectors Market in Netherlands 2019–2025 ($ million)

Exhibit 103          APAC Epinephrine Auto-injectors Market: Incremental & Absolute Growth

Exhibit 104          Epinephrine Auto-injectors Market in APAC 2019 ($ million)

Exhibit 105          Epinephrine Auto-injectors Market in APAC 2019–2025 ($ million)

Exhibit 106          APAC Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)

Exhibit 107          APAC Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)

Exhibit 108          Incremental Growth in APAC 2019 & 2025

Exhibit 109          Epinephrine Auto-injectors Market in Japan 2019–2025 ($ million)

Exhibit 110          Epinephrine Auto-injectors Market in Australia 2019–2025 ($ million)

Exhibit 111          Epinephrine Auto-injectors Market in South Korea 2019–2025 ($ million)

Exhibit 112          Epinephrine Auto-injectors Market in Middle East & Africa 2019 ($ million)

Exhibit 113          Middle East & Africa Epinephrine Auto-injectors Market: Incremental & Absolute Growth

Exhibit 114          Epinephrine Auto-injectors Market in Middle East & Africa 2019–2025 ($ million)

Exhibit 115          Middle East & Africa Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)

Exhibit 116          Middle East & Africa Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)

Exhibit 117          Incremental Growth in Middle East & Africa 2019 & 2025

Exhibit 118          Epinephrine Auto-injectors Market in Israel 2019–2025 ($ million)

Exhibit 119          Epinephrine Auto-injectors Market in South Africa 2019–2025 ($ million)

Exhibit 120          Epinephrine Auto-injectors Market in Turkey 2019–2025 ($ million)

Exhibit 121          Epinephrine Auto-injectors Market in Latin America 2019 ($ million)

Exhibit 122          Latin America Epinephrine Auto-injectors Market: Incremental & Absolute Growth

Exhibit 123          Epinephrine Auto-injectors Market in Latin America 2019–2025 ($ million)

Exhibit 124          Latin America Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)

Exhibit 125          Latin America Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)

Exhibit 126          Incremental Growth in Latin America 2019 & 2025

Exhibit 127          Epinephrine Auto-injectors Market in Brazil 2019–2025 ($ million)

Exhibit 128          Epinephrine Auto-injectors Market in Argentina 2019–2025 ($ million)

Exhibit 129          Global Epinephrine Auto-injectors Market: Vendors Market Share (2019)

Exhibit 130          Mylan: Sales by Geography 2019 (%)

Exhibit 131          Teva Pharmaceutical Industries: Revenue by Segment 2017 & 2018 ($ million)

Exhibit 132          Adamis Pharmaceuticals: R&D Expenditure 2016−2018 ($ million)

Exhibit 133          ALK-Abelló: Revenue by Product Line 2017 & 2018 ($ million)

Exhibit 134          ALK-Abelló: Revenue by Geography 2018 ($ million)

Exhibit 135          Novartis: R&D Expenditure 2016−2018 ($ million)

Exhibit 136          Novartis: Revenue by Segment 2017 & 2018 ($ million)

               

List Of Tables    

Table 1                  Key Caveats

Table 2                  Currency Conversion 2013−2019

Table 3                  Anaphylaxis Definitions Worldwide

Table 4                  Major Epinephrine Auto-injectors Under Development

Table 5                  Popular Patient Assistance Programs Offered by Vendors

Table 6                  Potential Advantages of Intravenous Epinephrine Delivery for Anaphylaxis Treatment

Table 7                  Global Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)

Table 8                  Significant Players Offering High Dose Epinephrine Auto-injectors

Table 9                  Significant Players Offering Low Dose Epinephrine Auto-injectors

Table 10               Global Epinephrine Auto-injectors Market by Age Group 2019−2025 ($ million)

Table 11               Significant Players Offering Epinephrine Auto-injectors for Patients Above 12 Years

Table 12               Significant Players Offering Epinephrine Auto-injectors for Patients in the Age Group of 6−12 Years

Table 13               Significant Players Offering Epinephrine Auto-injectors for Below 6 Years Patient Group

Table 14               Global Epinephrine Auto-injectors Market by End-user 2019−2025 ($ million)

Table 15               Global Epinephrine Auto-injectors Market by Geography 2019−2025 ($ million)

Table 16               North America Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)

Table 17               Europe Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)

Table 18               Incremental Growth by Dosage 2019 & 2025

Table 19               APAC Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)

Table 20               Incremental Growth by Dosage 2019 & 2025

Table 21               Middle East & Africa Epinephrine Auto-injectors market by Dosage 2019−2025 ($ million)

Table 22               Incremental Growth by Dosage 2019 & 2025

Table 23               Latin America Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)

Table 24               Competitive Structure Analysis of Global Epinephrine Auto-injectors Market 2019

Table 25               Global Epinephrine Auto-injectors Market: Vendor Ranking 2019

Table 26               Mylan: Major Product Offerings

Table 27               Teva Pharmaceutical Industries: Major Product Offerings

Table 28               Amneal Pharmaceuticals: Major Product Offerings

Table 29               Adamis Pharmaceuticals: Major Product Offerings

Table 30               ALK-Abelló: Major Product Offerings

Table 31               BIOPROJET PHARMAl: Major Product Offerings

Table 32               Bausch & Lomb: Major Product Offerings

Table 33               kaléo: Major Product Offerings

Table 34               Novartis: Major Product Offerings

Table 35               Global Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)

Table 36               Global Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)

Table 37               Global Epinephrine Auto-injectors Market by Age Group 2019−2025 ($ million)

Table 38               Global Epinephrine Auto-injectors Market by Age Group 2019−2025 (%)

Table 39               Global Epinephrine Auto-injectors Market by End-user 2019−2025 ($ million)

Table 40               Global Epinephrine Auto-injectors Market by End-user 2019−2025 (%)

Table 41               Global Epinephrine Auto-injectors Market by Geography 2019−2025 ($ million)

Table 42               Global Epinephrine Auto-injectors Market by Geography 2019−2025 (%)

Table 43               North America Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)

Table 44               North America Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)

Table 45               Europe Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)

Table 46               Europe Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)

Table 47               APAC Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)

Table 48               APAC Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)

Table 49               Middle East & Africa Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)

Table 50               Middle East & Africa Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)

Table 51               Latin America Epinephrine Auto-injectors Market by Dosage 2019−2025 ($ million)

Table 52               Latin America Epinephrine Auto-injectors Market by Dosage 2019−2025 (%)

Select a license type that suits your business needs

single-user Single User Licence
$3500.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$4000.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$5000.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$2000.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Prebook Tag
Licence Types What are these?
10 % OFF

on buying this report before the release date

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date